Quest Diagnostics Incorporated: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-05-22
Other years: 2026 vs 2025 · 2024 vs 2023
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Quest Diagnostics added one new risk factor in 2025 focused on U.S. regulatory and policy changes affecting healthcare, reflecting heightened concern about legislative developments. The company substantively modified five existing risks, with notable updates to disclosures on IT system vulnerabilities and evolving healthcare market dynamics. Together, these changes suggest Quest is intensifying its focus on regulatory uncertainty and operational resilience in an increasingly volatile healthcare environment.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
0
Removed
5
Modified
21
Unchanged
🟢 New in Current Filing Significant changes or developments in U.S. laws or policies, including changes in U.S. healthcare regulation, may have a material adverse effect on our business. 🔒
🟡 Modified Hardware and software failures or delays in our IT systems, including failures resulting from our systems conversions, services and support provided by third parties, or otherwise, could disrupt our operations and cause the loss of confidential information, customers and business opportunities or otherwise adversely impact our business. 🔒
🟡 Modified The U.S. healthcare system continues to evolve, and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt. 🔒
🟡 Modified Failure to develop, acquire licenses for, introduce, or commercialize new tests, technology and services could negatively impact our testing volume, revenues and profitability. 🔒
🟡 Modified Our business and operations could be adversely impacted by the FDA's approach to regulation. 🔒
🟡 Modified Our approach to corporate responsibility may not satisfy all our stakeholders. 🔒
6 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →